Administration of Low-dose Resveratrol Attenuated Hepatic Inflammation and Lipid Accumulation in High Cholesterol-fructose Diet-induced Rat Model of Nonalcoholic Fatty Liver Disease

10.4103/CJP.CJP_43_20

Chih-Chun Chang；Chieh-Yu Chang；Pei-Chun Lin；Jiung-Pang Huang；Kuan-Hsing Chen；Tzung-Hai Yen；Li-Man Hung

High cholesterol-fructose diet ； inflammation ； interleukin ； nonalcoholic fatty liver disease ； resveratrol ； STAT3

The Chinese Journal of Physiology

63卷4期（2020 / 08 / 31）

149 - 155

英文

Resveratrol (RSV) has been demonstrated to ameliorate nonalcoholic fatty liver disease (NAFLD) in animal studies. However, RSV was given with the dosage that ranged from 7 to 300 mg/kg body weight (BW). Hence, the study aimed to investigate the efficacy of RSV at a lower dosage on high cholesterol-fructose diet (HCFD)-induced rat model of NAFLD. In the study, male Sprague-Dawley rats were fed with HCFD for 15 weeks. RSV was also given at a daily dose of 1 mg/kg BW for 15 days or 15 weeks by oral delivery. At sacrifice, plasma and liver specimens were acquired for detections of alanine and aspartate aminotransferases, proinflammatory cytokines, and lipid contents. Histological examinations and Western blotting analysis were performed using liver tissues. The results showed that RSV administration reduced plasma levels of aminotransferases and proinflammatory cytokines including interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) in HCFD-induced NAFLD. RSV also mitigated hepatic lipid accumulation and expression of IL-1β, IL-6, and TNF-α. Besides, phosphorylation of signal transducer and activator of transcription 3 (STAT3) was reduced with RSV supplementation in the liver of HCFD-fed rats. We concluded that low-dose RSV supplementation attenuated hepatic inflammation and lipid accumulation in HCFD-induced NAFLD. The ameliorative effect of RSV on NAFLD could be associated with downregulation of phosphorylated STAT3.

1. Chang, CC,Chang, CY,Huang, JP,Hung, LM(2012).Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats.Chin J Physiol,55,192-201.
   連結：
2. Ahmed, A,Wong, RJ,Harrison, SA(2015).Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes.Clin Gastroenterol Hepatol,13,2062-2070.
3. Bagul, PK,Middela, H,Matapally, S,Padiya, R,Bastia, T,Madhusudana, K(2012).Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats.Pharmacol Res,66,260-268.
4. Baur, JA,Pearson, KJ,Price, NL,Jamieson, HA,Lerin, C,Kalra, A(2006).Resveratrol improves health and survival of mice on a high-calorie diet.Nature,444,337-342.
5. Brasnyó, P,Molnár, GA,Mohás, M,Markó, L,Laczy, B,Cseh, J(2011).Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.Br J Nutr,106,383-389.
6. Bujanda, L,Hijona, E,Larzabal, M,Beraza, M,Aldazabal, P,García-Urkia, N(2008).Resveratrol inhibits nonalcoholic fatty liver disease in rats.BMC Gastroenterol,8,40.
7. Chachay, VS,Macdonald, GA,Martin, JH,Whitehead, JP,O’Moore-Sullivan, TM,Lee, P(2014).Resveratrol does not benefit patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol,12,2092-2093.
8. Chang, CC,Lin, KY,Peng, KY,Day, YJ,Hung, LM(2016).Resveratrol exerts anti‑obesity effects in high‑fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3‑L1 cells.Endocr J,63,169-178.
9. Charytoniuk, T,Drygalski, K,Konstantynowicz-Nowicka, K,Berk, K,Chabowski, A(2017).Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials.Nutrition,34,108-117.
10. Chen, S,Zhao, X,Ran, L,Wan, J,Wang, X,Qin, Y(2015).Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial.Dig Liver Dis,47,226-232.
11. Deng, JY,Hsieh, PS,Huang, JP,Lu, LS,Hung, LM(2008).Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways.Diabetes,57,1814-1823.
12. Donaldson, J,Ngema, M,Nkomozepi, P,Erlwanger, K(2019).Quercetin administration post-weaning attenuates high-fructose, high-cholesterol diet-induced hepatic steatosis in growing, female, Sprague Dawley rat pups.J Sci Food Agric,99,6954-6961.
13. Elgebaly, A,Radwan, IA,AboElnas, MM,Ibrahim, HH,Eltoomy, MF,Atta, AA(2017).Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis.J Gastrointestin Liver Dis,26,59-67.
14. Faghihzadeh, F,Adibi, P,Hekmatdoost, A(2015).The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study.Br J Nutr,114,796-803.
15. Gómez-Zorita, S,Fernández-Quintela, A,Macarulla, MT,Aguirre, L,Hijona, E,Bujanda, L(2012).Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.Br J Nutr,107,202-210.
16. Hałoń, A,Patrzałek, D,Rabczyński, J(2006).Hepatic steatosis in liver transplant donors: Rare phenomenon or common feature of donor population?.Transplant Proc,38,193-195.
17. Heebøll, S,Kreuzfeldt, M,Hamilton-Dutoit, S,Kjær, Poulsen, M,Stødkilde-Jørgensen, H,Møller, HJ(2016).Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease.Scand J Gastroenterol,51,456-464.
18. Heebøll, S,Thomsen, KL,Pedersen, SB,Vilstrup, H,George, J,Grønbæk, H(2014).Effects of resveratrol in experimental and clinical non‑alcoholic fatty liver disease.World J Hepatol,6,188-198.
19. Lazo, M,Hernaez, R,Eberhardt, MS,Bonekamp, S,Kamel, I,Guallar, E(2013).Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994.Am J Epidem,178,38-45.
20. Li, S,Bouzar, C,Cottet-Rousselle, C,Zagotta, I,Lamarche, F,Wabitsch, M(2016).Resveratrol inhibits lipogenesis of 3T3-L1 and SGBS cells by inhibition of insulin signaling and mitochondrial mass increase.Biochim Biophys Acta,1857,643-652.
21. Lozano, I,van der Werf, R,Bietiger, W,Seyfritz, E,Peronet, C,Pinget, M(2016).High-fructose and high-fat diet-induced disorders in rats: Impact on diabetes risk, hepatic and vascular complications.Nutr Metab,13,15.
22. Machado, MV,Diehl, AM(2016).Pathogenesis of nonalcoholic steatohepatitis.Gastroenterology,150,1769-1777.
23. Mikuła‑Pietrasik, J,Kuczmarska, A,Rubiś, B,Filas, V,Murias, M,Zieliński, P(2012).Resveratrol delays replicative senescence of human mesothelial cells via mobilization of antioxidative and DNA repair mechanisms.Free Radic Biol Med,52,2234-2245.
24. Nasr, P,Ignatova, S,Kechagias, S,Ekstedt, M(2018).Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies.Hepatol Commun,2,199-210.
25. Peñalva, R,Morales, J,González-Navarro, CJ,Larrañeta, E,Quincoces, G,Peñuelas, I(2018).Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles.Int J Mol Sci.,19,2816.
26. Rivera, L,Morón, R,Zarzuelo, A,Galisteo, M(2009).Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats.Biochem Pharmacol,77,1053-1063.
27. Sergides, C,Chirilă, M,Silvestro, L,Pitta, D,Pittas, A(2016).Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers.Exp Ther Med,11,164-170.
28. Shang, J,Chen, LL,Xiao, FX,Sun, H,Ding, HC,Xiao, H(2008).Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase.Acta Pharmacol Sin,29,698-706.
29. Su, HC,Hung, LM,Chen, JK(2006).Resveratrol, a red wine antioxidant, possesses an insulin‑like effect in streptozotocin‑induced diabetic rats.Am J Physiol Endocrinol Metab,290,E1339-E1346.
30. Taskinen, MR,Söderlund, S,Bogl, LH,Hakkarainen, A,Matikainen, N,Pietiläinen, KH(2017).Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.J Intern Med,282,187-201.
31. Tran, TT,Changsri, C,Shackleton, CR,Poordad, FF,Nissen, NN,Colquhoun, S(2006).Living donor liver transplantation: Histological abnormalities found on liver biopsies of apparently healthy potential donors.J Gastroenterol Hepatol,21,381-383.
32. Vinaixa, M,Rodríguez, MA,Rull, A,Beltrán, R,Bladé, C,Brezmes, J(2010).Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease.J Proteome Res,9,2527-2538.
33. Wanless, IR,Lentz, JS(1990).Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors.Hepatology,12,1106-1110.
34. Williams, CD,Stengel, J,Asike, MI,Torres, DM,Shaw, J,Contreras, M(2011).Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study.Gastroenterology,140,124-131.
35. Yamamoto, K,Takada, Y,Fujimoto, Y,Haga, H,Oike, F,Kobayashi, N(2007).Nonalcoholic steatohepatitis in donors for living donor liver transplantation.Transplantation,83,257-262.
36. Younossi, ZM,Stepanova, M,Afendy, M,Fang, Y,Younossi, Y,Mir, H(2011).Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol,9,524-300.
37. Zhang, C,Yuan, W,Fang, J,Wang, W,He, P,Lei, J(2016).Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: A meta-analysis of placebo-controlled clinical trials.PLoS One,11,e0161792.